{"id":19586,"date":"2023-04-17T11:18:00","date_gmt":"2023-04-17T03:18:00","guid":{"rendered":"https:\/\/flcube.com\/?p=19586"},"modified":"2024-12-24T11:21:49","modified_gmt":"2024-12-24T03:21:49","slug":"legend-biotech-and-janssen-partner-with-novartis-on-carvykti-manufacturing-and-clinical-supply","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=19586","title":{"rendered":"Legend Biotech and Janssen Partner with Novartis on Carvykti Manufacturing and Clinical Supply"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Legend Biotech Corporation (<a href=\"https:\/\/www.google.com\/finance\/quote\/LEGN:NASDAQ\">NASDAQ: LEGN<\/a>), a China-based biotech firm, and its US partner Janssen Pharmaceutical have entered into a significant technology transfer, manufacturing, and clinical supply service agreement with Swiss pharmaceutical giant Novartis (<a href=\"https:\/\/www.google.com\/finance\/quote\/NVS:NYSE\">NYSE: NVS<\/a>). The agreement pertains to the co-developed CAR-T cell therapy, Carvykti (ciltacabtagene autoleucel; cilta-cel), and is set to span three years.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Details of the Agreement<\/strong><br>Under this agreement, Novartis will take on the manufacturing process for Carvykti, a BCMA-targeted chimeric antigen receptor (CAR) T cell therapy. This collaboration aims to enhance the manufacturing capabilities of both Legend and Janssen for CAR-T therapies, ensuring a more robust supply chain and potentially increasing the accessibility of this innovative treatment.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Carvykti&#8217;s Market Approvals and Sales Performance<\/strong><br>Carvykti achieved its first major market approvals in 2022, beginning with the US in March and followed by the European Medicines Agency (EMA) in May. The therapy is indicated for heavily pre-treated patients with relapsed\/refractory multiple myeloma (MM). As the drug awaits its first regulatory decision in China, it has already demonstrated strong sales, generating USD 55 million in the last quarter of 2022, according to Legend\u2019s financial report.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Conclusion<\/strong><br>The partnership between Legend Biotech, Janssen Pharmaceutical, and Novartis is a strategic move that underscores the global commitment to advancing CAR-T cell therapies. With Novartis&#8217;s manufacturing expertise, the agreement is poised to bolster the production and distribution of Carvykti, offering hope to patients with multiple myeloma worldwide.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Legend Biotech Corporation (NASDAQ: LEGN), a China-based biotech firm, and its US partner Janssen Pharmaceutical&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[21,1996,112,873,140,865],"class_list":["post-19586","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-car-t","tag-janssen","tag-legend-biotech","tag-nasdaq-legn","tag-novartis","tag-nyse-nvs"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Legend Biotech and Janssen Partner with Novartis on Carvykti Manufacturing and Clinical Supply - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Legend Biotech Corporation (NASDAQ: LEGN), a China-based biotech firm, and its US partner Janssen Pharmaceutical have entered into a significant technology transfer, manufacturing, and clinical supply service agreement with Swiss pharmaceutical giant Novartis (NYSE: NVS). The agreement pertains to the co-developed CAR-T cell therapy, Carvykti (ciltacabtagene autoleucel; cilta-cel), and is set to span three years.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=19586\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Legend Biotech and Janssen Partner with Novartis on Carvykti Manufacturing and Clinical Supply\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=19586\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-17T03:18:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-24T03:21:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19586#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19586\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Legend Biotech and Janssen Partner with Novartis on Carvykti Manufacturing and Clinical Supply\",\"datePublished\":\"2023-04-17T03:18:00+00:00\",\"dateModified\":\"2024-12-24T03:21:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19586\"},\"wordCount\":248,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"CAR-T\",\"Janssen\",\"Legend Biotech\",\"NASDAQ: LEGN\",\"Novartis\",\"NYSE: NVS\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=19586#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19586\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=19586\",\"name\":\"Legend Biotech and Janssen Partner with Novartis on Carvykti Manufacturing and Clinical Supply - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-04-17T03:18:00+00:00\",\"dateModified\":\"2024-12-24T03:21:49+00:00\",\"description\":\"Legend Biotech Corporation (NASDAQ: LEGN), a China-based biotech firm, and its US partner Janssen Pharmaceutical have entered into a significant technology transfer, manufacturing, and clinical supply service agreement with Swiss pharmaceutical giant Novartis (NYSE: NVS). The agreement pertains to the co-developed CAR-T cell therapy, Carvykti (ciltacabtagene autoleucel; cilta-cel), and is set to span three years.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19586#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=19586\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19586#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Legend Biotech and Janssen Partner with Novartis on Carvykti Manufacturing and Clinical Supply\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Legend Biotech and Janssen Partner with Novartis on Carvykti Manufacturing and Clinical Supply - Insight, China&#039;s Pharmaceutical Industry","description":"Legend Biotech Corporation (NASDAQ: LEGN), a China-based biotech firm, and its US partner Janssen Pharmaceutical have entered into a significant technology transfer, manufacturing, and clinical supply service agreement with Swiss pharmaceutical giant Novartis (NYSE: NVS). The agreement pertains to the co-developed CAR-T cell therapy, Carvykti (ciltacabtagene autoleucel; cilta-cel), and is set to span three years.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=19586","og_locale":"en_US","og_type":"article","og_title":"Legend Biotech and Janssen Partner with Novartis on Carvykti Manufacturing and Clinical Supply","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=19586","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-04-17T03:18:00+00:00","article_modified_time":"2024-12-24T03:21:49+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=19586#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=19586"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Legend Biotech and Janssen Partner with Novartis on Carvykti Manufacturing and Clinical Supply","datePublished":"2023-04-17T03:18:00+00:00","dateModified":"2024-12-24T03:21:49+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=19586"},"wordCount":248,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["CAR-T","Janssen","Legend Biotech","NASDAQ: LEGN","Novartis","NYSE: NVS"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=19586#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=19586","url":"https:\/\/flcube.com\/?p=19586","name":"Legend Biotech and Janssen Partner with Novartis on Carvykti Manufacturing and Clinical Supply - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-04-17T03:18:00+00:00","dateModified":"2024-12-24T03:21:49+00:00","description":"Legend Biotech Corporation (NASDAQ: LEGN), a China-based biotech firm, and its US partner Janssen Pharmaceutical have entered into a significant technology transfer, manufacturing, and clinical supply service agreement with Swiss pharmaceutical giant Novartis (NYSE: NVS). The agreement pertains to the co-developed CAR-T cell therapy, Carvykti (ciltacabtagene autoleucel; cilta-cel), and is set to span three years.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=19586#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=19586"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=19586#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Legend Biotech and Janssen Partner with Novartis on Carvykti Manufacturing and Clinical Supply"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19586","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=19586"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19586\/revisions"}],"predecessor-version":[{"id":19587,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19586\/revisions\/19587"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=19586"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=19586"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=19586"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}